Miller Howard Investments Inc. NY Sells 10,115 Shares of Medtronic PLC $MDT

Miller Howard Investments Inc. NY cut its holdings in Medtronic PLC (NYSE:MDT) by 1.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 723,893 shares of the medical technology company’s stock after selling 10,115 shares during the period. Medtronic makes up 2.1% of Miller Howard Investments Inc. NY’s investment portfolio, making the stock its 12th largest position. Miller Howard Investments Inc. NY’s holdings in Medtronic were worth $69,537,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Artisan Partners Limited Partnership lifted its holdings in shares of Medtronic by 2.6% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after buying an additional 31,314 shares during the period. SageView Advisory Group LLC lifted its holdings in shares of Medtronic by 164.8% during the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock valued at $2,305,000 after buying an additional 15,062 shares during the period. CSM Advisors LLC lifted its holdings in shares of Medtronic by 13.2% during the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock valued at $27,169,000 after buying an additional 33,167 shares during the period. UMB Bank n.a. lifted its holdings in shares of Medtronic by 65.8% during the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after buying an additional 54,898 shares during the period. Finally, Applied Finance Capital Management LLC bought a new position in shares of Medtronic during the 3rd quarter valued at $1,308,000. 82.06% of the stock is owned by institutional investors.

Medtronic Price Performance

Shares of Medtronic stock opened at $86.24 on Monday. Medtronic PLC has a one year low of $79.93 and a one year high of $106.33. The stock’s fifty day moving average is $91.51 and its 200 day moving average is $95.71. The stock has a market cap of $110.72 billion, a P/E ratio of 24.02, a P/E/G ratio of 2.24 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same period last year, the firm earned $1.38 EPS. Medtronic’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MDT. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Stifel Nicolaus lowered their price target on Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Monday, April 6th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Truist Financial lowered their price target on Medtronic from $103.00 to $95.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Finally, UBS Group reissued a “neutral” rating and set a $104.00 price target on shares of Medtronic in a report on Wednesday, February 4th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus price target of $109.25.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).